We use cookies on our website. Carry on browsing if you’re happy with this or find out more



We are utilizing our technology platforms to develop product candidates for immune disorders, cancer and haematological diseases.

We are developing therapeutics designed to modulate the immune system, to overcome cancer immune tolerance and escape. We are also developing therapeutics designed to treat autoimmune diseases.

Amlitelimab SAR445229 (formerly KY1005), Alomfilimab SAR445256 (formerly KY1044) and KY1043 are designed to balance the activation and suppression of the immune system to treat disease.

Our pipeline

We are building a rich pipeline of assets in four main therapeutic spaces: immune diseases, immuno-oncology, haematology and infectious diseases.

Download Pipeline PDF

Sanofi and Kymab have joined forces to bring new medicines to patients.

Read the press release